Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00536783 · ClinicalTrials.gov registry record
Schizophrenia Sensory Gating Deficit With Quetiapine
A clinical trial, sponsored by New Mexico VA Healthcare System.
- Completed
- Registry status
- 20
- Enrollment target
NCT00536783: Completed study, sponsored by New Mexico VA Healthcare System.
NCT00536783 is a clinical trial that has completed, run by New Mexico VA Healthcare System. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00536783 has completed, sponsored by New Mexico VA Healthcare System.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to study how sounds are processed in individuals with schizophrenia after three months of taking the antipsychotic medication quetiapine.
Interventions
- DRUG Quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-03 |
What the finished NCT00536783 record still lists
NCT00536783 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Quetiapine is the first listed.
NCT00536783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00536783 about?
NCT00536783 is a clinical study titled "Schizophrenia Sensory Gating Deficit With Quetiapine". The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to study how sounds are processed in individuals with schizophrenia after th...
What is the current status of trial NCT00536783?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2004-04. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00536783?
The interventions under investigation include: Quetiapine (DRUG).
Who is sponsoring clinical trial NCT00536783?
This trial is sponsored by New Mexico VA Healthcare System, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia